Condition: Prostaatgezondheid

What It Is

The prostate is a walnut-sized gland that sits just below the bladder and wraps around the urethra, the tube urine passes through. Three separate problems share the one word. Telling them apart is most of the work, because what helps depends entirely on which one a man has.

Benign prostatic hyperplasia is the common one, the ordinary non-cancerous growth of the gland with age. As it enlarges it presses on the urethra and produces the familiar urinary symptoms:

• a weak or stop-start stream,
• going more often,
• waking at night to urinate,
• a sense the bladder never fully empties.

It is not cancer and does not turn into cancer, though a man can have both at once. Its full treatment is covered on Enlarged Prostate (BPH).

Prostatitis is one name for two very different problems. Acute bacterial prostatitis brings fever together with urinary pain and needs antibiotics quickly. Chronic pelvic pain syndrome is far more common and is not an infection. Its care aims at several symptoms at once.

Prostate cancer is a separate question again, usually slow-growing and picked up by a PSA blood test before it causes symptoms. The two decisions are whether to have the test at all, and if a low-risk cancer turns up, whether to treat it now or watch it.

What Helps an Enlarged Prostate

For the everyday urinary symptoms of an enlarged prostate, the first moves are a man's own. Regular physical activity tracks with less prostate enlargement and fewer urinary symptoms across 19 studies. Almost all of that evidence is observational, so it points to a strong association without proving cause. Exercise also drives the weight loss and better metabolic health that help on their own.

A few evening habits cut the night-time waking that bothers men most:

• shift most of your fluids to earlier in the day,
• ease back on caffeine and alcohol in the evening,
• take unhurried time on the toilet.

When the basics are not enough, two drug classes add to them. Alpha-blockers such as tamsulosin or doxazosin relax the muscle around the prostate and bladder neck, easing the stream within days to weeks. They are the usual first medication when the stream is the main complaint.

In the MTOPS trial of 3,047 men, doxazosin improved symptoms and cut the risk of the condition getting worse by 39% against placebo. Alpha-blockers do not shrink the gland, so on their own they did not lower the rate of a sudden blockage or the need for surgery.

The gland-shrinking drugs work on the other half of the problem. Finasteride and dutasteride, the 5-alpha-reductase inhibitors, block the hormone that drives prostate growth and shrink an enlarged gland over months.

In MTOPS, finasteride cut progression by 34%. Combining it with an alpha-blocker cut progression by two thirds, or 66%. Finasteride was the drug that lowered acute urinary retention and the need for surgery, an effect that held across six years of follow-up. For a large gland at high risk of blockage, the combination is the strongest option: one drug gives fast relief while the other shrinks the prostate.

That benefit carries a cost. A pooled analysis found the symptom gain from the gland-shrinking drugs over placebo was statistically clear but small. It came with sexual side effects: lower libido, erectile difficulty, and reduced ejaculate. For most men these settle over time, or reverse when the drug is stopped. A minority report changes that persist. These drugs also roughly halve the measured PSA, so any screening result taken while on one has to be doubled to be read correctly.

Chronic pelvic pain syndrome, the most common form of prostatitis, is the outlier: it has no dependable drug. A network meta-analysis of 25 trials found only weak evidence for any single treatment, with alpha-blockers edging out placebo but nothing working reliably. Care here treats the urinary, pain, and pelvic-floor symptoms together, focused on whichever symptoms are worst.

The Supplements: Saw Palmetto and Beta-Sitosterol

Saw palmetto is the most tested prostate supplement. For years it was recommended in place of prescription drugs. In the strong trials it did nothing:

• In the STEP trial it beat a dummy pill by 0.04 point on the standard urinary symptom score, a difference that amounts to nothing.
• The CAMUS trial pushed the dose to three times standard and still found no benefit over placebo (Barry and colleagues, JAMA, 2011).
• The 2023 Cochrane review concludes it gives little to no benefit (Franco and colleagues, Cochrane Database of Systematic Reviews, 2023).

Saw palmetto is harmless, so a man already taking it loses nothing.

Beta-sitosterol, a plant compound, has better short-term data than saw palmetto, though far less than its marketing claims. A Cochrane review of four trials in 519 men found it improved symptom scores by about 4.9 points and peak urine flow by about 3.9 mL per second over placebo. It did not shrink the gland. The trials ran only weeks. The reviewers were clear that long-term effectiveness, safety, and any ability to prevent the blockages and surgery the prescription drugs prevent were never tested.

So it is a modest short-term helper at most. Prostate products sold online also carry a documented record of adulteration with undeclared drugs, so anything herbal belongs with a traceable supply.

The PSA Screening Decision

Whether to have a PSA test is a close call, and the two largest trials are why. The European trial, ERSPC, followed 162,236 men aged 55 to 69 for 23 years. It found prostate-cancer death 13% lower in the men offered repeated testing, or one death prevented for every 456 men invited to screening. The US trial, PLCO, randomized 76,683 men to annual testing or usual care. It found no significant reduction in prostate-cancer death, with a rate ratio of 0.93.

The two trials look like they disagree, but the difference has a simple explanation. A large share of the PLCO usual-care group got PSA tests anyway, so any real benefit was masked.

The harms fall on the screening side. PSA screening finds many cancers that would never have caused harm, and treating them carries consequences. US Preventive Services Task Force figures put the benefit at about 1.3 fewer prostate-cancer deaths for every 1,000 men screened over 13 years.

Against that, roughly 1 in 5 treated men are left with lasting urinary incontinence, and 2 in 3 with lasting erectile difficulty.

That imbalance of overdiagnosis and overtreatment is why the Task Force made screening a shared decision for men aged 55 to 69. It recommended against screening for men 70 and older. The decision weighs a man's age, family history, and how much he values the modest benefit against the harms.

Finding a cancer no longer forces immediate treatment. In the ProtecT trial, men with localized PSA-detected cancer who were monitored closely had the same 15-year survival as men treated at once with surgery or radiotherapy. At the end, 24.4% of the monitored men were still alive with no cancer treatment at all. Active surveillance is a sound, evidence-backed path for low-risk disease, and a new diagnosis is rarely an emergency. Monitoring did carry a higher risk that the cancer would spread, a tradeoff worth weighing.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Genitourinary

Alpha-blockers ease the stream in days and cut BPH progression 39%Strong

In plain terms

Alpha-blockers such as doxazosin and tamsulosin relax the muscle around the prostate and bladder neck, easing the urinary stream within days to weeks. In the large MTOPS trial they improved symptoms and cut clinical progression by about 39%.

In detail

In the MTOPS trial, 3,047 men were randomized to placebo, doxazosin, finasteride, or both and followed a mean 4.5 years. Doxazosin cut the risk of overall clinical progression, defined as a rise of at least 4 points in the American Urological Association symptom score, acute retention, incontinence, renal insufficiency, or recurrent infection, by 39% against placebo, and improved symptom scores significantly. Alpha-blockers work fast because they relax smooth muscle, not shrinking the gland, which is why they help symptoms but did not, on their own, reduce acute urinary retention or the need for invasive treatment in this trial.

How to use it

Alpha-blockers are the usual first medication when symptoms are the main problem and the gland is not very large, because relief comes quickly. Standing up slowly in the first days limits the dizziness, and the change in ejaculation is common and reversible on stopping.

The study · 1

McConnell et al. (MTOPS), long-term effect of doxazosin, finasteride and combination therapy on clinical progression of benign prostatic hyperplasia · N Engl J Med 2003;349(25):2387-2398

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Finasteride cuts BPH progression 34%, combined with an alpha-blocker 66%Strong

In plain terms

Finasteride and dutasteride shrink an enlarged prostate over months. In MTOPS, finasteride cut clinical progression by about a third and combining it with an alpha-blocker cut it by two thirds, and finasteride was the arm that lowered acute urinary retention and surgery.

In detail

In MTOPS, finasteride reduced the risk of overall clinical progression by 34% and combination therapy by 66% against placebo, with combination superior to either drug alone. Finasteride and combination therapy, but not doxazosin, significantly reduced acute urinary retention and the need for invasive therapy. The PLESS study showed that lower rate of retention and surgery held up across 6 years. These drugs block conversion of testosterone to dihydrotestosterone and shrink the gland, so they help most when the prostate is enlarged and take months, not days to act. They also roughly halve the measured PSA, so a screening result taken while on one has to be doubled to be read correctly.

How to use it

A 5-alpha-reductase inhibitor is the choice when the gland is large and the goal is to prevent retention or surgery, often paired with an alpha-blocker for early symptom relief while the shrinkage catches up. Tell any clinician ordering a PSA that you take one.

The studies · 2

McConnell et al. (MTOPS), long-term effect of doxazosin, finasteride and combination therapy on clinical progression of benign prostatic hyperplasia · N Engl J Med 2003;349(25):2387-2398

Roehrborn et al. (PLESS), sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years · J Urol 2004;171(3):1194-1198

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Saw palmetto beat placebo by just 0.04 point, and failed even at triple doseStrong · no effect

In plain terms

The common advice to take saw palmetto for the prostate has not held up. In good placebo-controlled trials, including one that pushed the dose to three times standard, it worked no better than a dummy pill, and the current Cochrane review agrees.

In detail

Saw palmetto is used by millions of men and was long recommended as an alternative to prescription drugs. Better trials revised that. The STEP trial randomized 225 men to saw palmetto or placebo for a year and found a difference in the American Urological Association symptom score of 0.04 points, with no difference in flow rate, prostate size, or residual volume. The CAMUS trial then took 369 men up to three times the standard 320 mg daily dose and still found no benefit over placebo. The 2023 Cochrane review, updating a comprehensive search, concludes Serenoa repens does not improve urinary symptoms compared with placebo. The early positive reports came from smaller, lower-quality studies, which is where the reputation was built.

How to use it

If saw palmetto is already part of a routine it is not dangerous, but it is not doing the work its reputation claims. Money and hope are better spent on the measures that do move symptoms, and on a conversation about the medications that prevent retention and surgery.

The studies · 3

Franco et al., Serenoa repens for lower urinary tract symptoms due to benign prostatic enlargement (Cochrane review) · Cochrane Database Syst Rev 2023;6:CD001423

Barry et al. (CAMUS), effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial · JAMA 2011;306(12):1344-1351

Bent et al. (STEP), saw palmetto for benign prostatic hyperplasia · N Engl J Med 2006;354(6):557-566

Beta-sitosterol eased symptoms 4.9 points short-term, with no long-term dataEmerging

In plain terms

Beta-sitosterol has better short-term data than saw palmetto: a Cochrane review found it improved symptoms and flow over placebo. It has no long-term evidence, and its marketing claims far more than the trials tested.

In detail

A Cochrane review pooled 4 randomized, placebo-controlled trials of beta-sitosterol in 519 men lasting 4 to 26 weeks. It improved urinary symptom scores by a weighted mean of 4.9 IPSS points and peak urine flow by about 3.9 mL per second, and reduced post-void residual volume, but it did not reduce prostate size. The reviewers were explicit that long-term effectiveness, safety, and any ability to prevent BPH complications are unknown, because no trial ran long enough to test them. So the short-term signal is present but rests on old and brief studies, a narrower claim than its marketing makes.

How to use it

If a plant supplement is wanted, beta-sitosterol has more behind it than saw palmetto for short-term symptoms, but it is not a substitute for the drugs that prevent retention, and it should not be read as protecting the prostate over years, which was never tested.

The study · 1

Wilt et al., beta-sitosterols for benign prostatic hyperplasia (Cochrane review) · Cochrane Database Syst Rev 2000;(2):CD001043

Active men have less prostate enlargement across 19 studies, all observationalEmerging

In plain terms

Men who are more physically active tend to have less prostate enlargement and fewer urinary symptoms. The link is consistent enough to act on and comes from observational data, so it is an association, not proof.

In detail

A 2026 review gathered 19 human studies, 17 observational plus one meta-analysis and one Mendelian randomization study, on physical activity and benign prostatic hyperplasia. Moderate-intensity exercise appeared to offer more protection than high-intensity exercise, and moderate-to-high general activity was associated with lower BPH risk in most, though not all, studies. Because almost all of it is observational, healthy-user and reverse-causation bias apply: active men are leaner and healthier to begin with, and urinary symptoms can themselves cut activity down. There is no randomized trial. Given that activity carries broad benefits and no meaningful downside here, do it whether or not the prostate-specific link proves causal.

How to use it

Regular moderate activity, roughly the amount already recommended for the heart and metabolism, is the version with the most support here. It overlaps with the weight and metabolic control that also track with prostate symptoms, so one habit covers several fronts.

The study · 1

Exercise and physical activity as modifiable risk factors for benign prostatic hyperplasia: an update · Curr Urol Rep 2026

Cancer Risk And Outcome

Monitoring localized cancer matched surgery on 15-year survival, 24.4% never needed treatmentStrong · mixed

In plain terms

For localized prostate cancer found by PSA, watching it closely gave the same 15-year survival as immediate surgery or radiotherapy. Monitoring carried a higher chance of the cancer spreading, and about a quarter of monitored men never needed any treatment.

In detail

ProtecT randomized 1,643 men with PSA-detected localized prostate cancer to active monitoring, radical prostatectomy, or radiotherapy. At a median 15 years, death from prostate cancer was low and did not differ significantly between groups: 3.1% with monitoring, 2.2% with surgery, 2.9% with radiotherapy, 2.7% overall, and death from any cause was similar. Monitoring did carry more metastases, 9.4% versus about 5% in the treated arms, and more disease progression. But 24.4% of the monitored men were alive with no prostate-cancer treatment at the end of follow-up, having avoided the incontinence and erectile harms of surgery and radiotherapy entirely. The finding held across baseline PSA, stage, and risk score. This is the trial that made active surveillance a mainstream option for low-risk disease.

How to use it

A new low-risk diagnosis is rarely an emergency. Active surveillance, structured monitoring with the option to treat if the cancer changes, is a reasonable and evidence-backed path, and the tradeoff to weigh with the team is a higher chance of spread against avoiding treatment harms.

The studies · 2

Hamdy et al. (ProtecT), fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer · N Engl J Med 2023;388(17):1547-1558

Hamdy et al. (ProtecT), 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer · N Engl J Med 2016;375(15):1415-1424

Measurement And Diagnosis

PSA screening cut prostate-cancer death 13%, one prevented per 456 men invitedModerate

In plain terms

PSA screening does lower the chance of dying from prostate cancer, by about 13% over 23 years in the largest trial. In absolute terms that meant one death prevented for every 456 men invited, so the benefit is modest.

In detail

The European Randomized Study of Screening for Prostate Cancer followed a core group of 162,236 men aged 55 to 69 for a median 23 years. Prostate-cancer mortality was 13% lower in the group offered repeated PSA testing (rate ratio 0.87, 95% CI 0.80 to 0.95), an absolute risk reduction of 0.22%. That works out to one prostate-cancer death prevented for every 456 men invited to screening, and one death averted for every 12 men diagnosed, both figures improving as follow-up lengthened. The cumulative incidence of prostate cancer was about 30% higher in the screened group, which is the overdiagnosis that rides alongside the benefit. The authors call for risk-based screening to keep the benefit while cutting that overdiagnosis.

How to use it

The mortality benefit holds, which is why screening is offered. Its modest absolute size and the overdiagnosis attached to it are why the decision is shared, not automatic, and why who benefits most, by age and risk, matters.

The study · 1

Roobol, Hugosson et al. (ERSPC), European study of prostate cancer screening: 23-year follow-up · N Engl J Med 2025;393(17):1669-1680

A second trial, PLCO, found no PSA mortality benefit (rate ratio 0.93)Moderate · no effect

In plain terms

A second large trial, the US PLCO study, found no clear reduction in prostate-cancer death from annual screening. Much of its comparison group got PSA tests too, which is the main reason the two big trials seem to disagree.

In detail

The Prostate, Lung, Colorectal and Ovarian trial randomized 76,683 men to annual PSA screening or usual care. After a median of nearly 17 years there was no significant reduction in prostate-cancer mortality in the screened arm (rate ratio 0.93, 95% CI 0.81 to 1.08), with more low-grade Gleason 2 to 6 disease detected and slightly less high-grade disease. The catch is contamination: a large fraction of the usual-care group had PSA testing outside the study, so the trial partly compared screening with screening, which blunts any true difference. Read together with the European trial, the picture is a modest benefit that a heavily contaminated comparison can wash out, not evidence that screening does nothing.

How to use it

The two headline trials point the same way: a small true benefit, easy to lose when the comparison group is also getting tested. That is a reason to individualize the decision, not to abandon screening or to demand it universally.

The study · 1

Pinsky et al. (PLCO), extended follow-up for prostate cancer incidence and mortality in a randomized screening trial · BJU Int 2019;123(5):854-860

Pain

No single drug reliably treats chronic pelvic pain syndrome across 25 trialsEmerging · mixed

In plain terms

Chronic pelvic pain syndrome, the most common form of prostatitis, has no reliable drug fix. A network meta-analysis of 25 trials found only weak evidence for any single treatment, which is why care aims at several symptoms at once, not one pill.

In detail

Chronic prostatitis / chronic pelvic pain syndrome is a pain condition with no infection to treat and no enlargement to shrink, and it is diagnosed by excluding those. A network meta-analysis of 25 trials in 3,514 men found only low to very low quality evidence across 26 treatments. Alpha-blockers such as doxazosin, and some combinations, beat placebo on the NIH chronic prostatitis symptom index, but the authors concluded that pharmacological treatments have little evidence supporting efficacy and suggested personalizing therapy to each man's symptoms. That is the basis of the phenotype-directed approach, which addresses the urinary, pain, psychological, and pelvic-floor domains together instead of relying on one drug.

How to use it

Because no single drug is dependable, the useful move is a plan matched to which symptoms dominate, often combining a symptom-targeted medication with pelvic-floor physiotherapy and attention to stress and sleep, reviewed over weeks, not judged on one trial of one pill.

The study · 1

Qin et al., pharmacological therapy for chronic prostatitis/chronic pelvic pain syndrome · EClinicalMedicine 2022;48:101457

Go Deeper

• Enlarged Prostate (BPH): the full treatment, from fluid timing through the medications to the newer office procedures and surgery.
• Erectile dysfunction: where the sexual side effects of these medications fit, and the blood-flow causes behind most erection trouble.
• Testosterone therapy: the hormone behind prostate enlargement, and how the gland-shrinking drugs block it.

Cautions

Extra restraint

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

The gland-shrinking drugs work but bring common sexual side effects

A meta-analysis of 5-alpha-reductase inhibitor monotherapy in benign prostatic hyperplasia found a statistically significant but small clinical benefit against placebo, alongside a high rate of adverse events including sexual dysfunction: reduced libido, erectile difficulty, and reduced ejaculate volume. For most men these ease over time or reverse when the drug is stopped, but a minority report effects that persist. This cost sits against the strong progression data, which is why the choice is worth making deliberately.Kim et al., efficacy and safety of 5-alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis

Screening 1,000 men prevents about 1.3 deaths, but 1 in 5 treated men get lasting incontinence

The US Preventive Services Task Force reviewed the trials and modeling in 2018. Screening 1,000 men aged 55 to 69 for about 13 years prevents roughly 1.3 prostate-cancer deaths and about 3 cases of metastatic disease. Set against that, many screen-detected cancers would never have caused symptoms, and treating them carries clear harm: about 1 in 5 men who have their prostate removed develop long-term urinary incontinence, and about 2 in 3 develop long-term erectile dysfunction, with bowel effects after radiotherapy. On that balance the Task Force made screening an individual, shared decision for men 55 to 69 and recommended against it for men 70 and older. The active-surveillance data below is part of what softens this, since not every diagnosed cancer needs immediate treatment.US Preventive Services Task Force (Grossman et al.), screening for prostate cancer: recommendation statement

Suddenly being unable to pass urine is a same-day emergency

Acute urinary retention is a sudden inability to empty the bladder, typically with lower abdominal pain and a palpable full bladder, and benign prostatic hyperplasia is its most common cause in men. Guidelines, including the 2025 French Urological Association review, treat it as a urological emergency whose first step is immediate bladder drainage by catheter. It is one of the specific reasons a 5-alpha-reductase inhibitor is used long term, since finasteride and combination therapy lower the risk of it happening. Once it has happened, though, it needs same-day care, because sustained retention raises pressure back through the urinary tract and can damage the bladder wall and the kidneys.French Urological Association Male LUTS Panel (CTMH), management of acute urinary retention in men with benign prostatic hyperplasia: literature review and guidelines

Blood in the urine or semen needs a cancer check, not watchful waiting

The AUA and SUFU guideline defines microhematuria as at least 3 red blood cells per high-power field and stratifies patients into low, intermediate, and high risk for urinary-tract cancer based on age, sex, smoking, the amount of blood, and any prior visible bleeding. Higher-risk patients are advised to have cystoscopy and upper-tract imaging, with the decision shared. Visible blood in the urine warrants evaluation in its own right. Most cases turn out to have a benign cause, but the reason the workup exists is that hematuria can be the presenting sign of bladder, kidney, or prostate cancer, and that possibility is what earns it a look, not reassurance.Barocas et al., microhematuria: AUA/SUFU guideline

Fever with urinary symptoms can mean acute bacterial prostatitis, treated with antibiotics

Prostatitis falls into four categories: acute bacterial, chronic bacterial, chronic prostatitis / chronic pelvic pain syndrome, and asymptomatic. Acute bacterial prostatitis is the one caused by infection, with fever and urinary pain, frequency, or difficulty, and it is diagnosed from the history and microbiological testing and treated with antibiotics, with the course guided by how long symptoms have run and whether there are complications. It is distinct from chronic pelvic pain syndrome, which is the most common form, is not an infection, and is a diagnosis of exclusion with no standardized treatment. For a reader the line is simple: fever plus urinary symptoms is a reason to seek care promptly, not to reach for the measures meant for a benign enlarged prostate.Lam & Stokes, acute and chronic prostatitis

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

When to See Someone

The everyday version is a matter of symptoms and choices. A handful of situations are different and need care the same day or sooner:

• A sudden and painful inability to pass urine, with a full, tense bladder. This is acute urinary retention, a urological emergency. The bladder must be drained with a catheter that day; it will not clear on its own and can harm the kidneys(seek urgent care)
• Fever with painful, frequent or difficult urination. This can mean acute bacterial prostatitis, which needs prompt antibiotics(seek urgent care)
• Visible blood in the urine or semen. It often has a harmless cause, but because it can be the first sign of a bladder, kidney or prostate cancer, it needs assessment(seek urgent care)
• New bone pain (back or hips) or unplanned weight loss in someone with known prostate cancer. This can point to spread and needs assessment
• Urinary symptoms that worsen over days, not the usual slow change over months
• A raised PSA, or a decision about whether to be tested at all, which is a conversation to have with a doctor before arranging or interpreting a test

None of this is a reason to worry about ordinary urinary symptoms. They are common and very treatable. Know the few signs that need faster action, and treat the PSA question as a shared decision made with a doctor.